Bliss GVS Pharma to Deduct Tax on Dividend Payable in FY 2026-27
Bliss GVS Pharma recommended a final dividend of Re. 1.00 per equity share for FY 2025-26. The dividend is payable post-approval at the 41st AGM on July 15, 2026. Record date is July 08, 2026. Shareholders must comply with TDS regulations as dividend income is taxable. Documents for tax deduction are due by July 08, 2026.
The announcement details tax implications for shareholders on dividend income, which requires specific actions and documentation from them. While not directly impacting the company's financials, it affects shareholder procedures and compliance.
The announcement is primarily informational regarding tax implications on dividend payouts and does not contain positive or negative financial news. It outlines procedures and compliance requirements.
Bliss GVS Pharma Limited has issued a communication to its shareholders regarding the applicability of tax deduction on dividends. The Board of Directors, in their meeting on May 12, 2026, recommended a Final Dividend of Re. 1.00 per equity share for the Financial Year ended March 31, 2026. This dividend is subject to shareholder approval at the 41st Annual General Meeting (AGM) scheduled for July 15, 2026.
The company has fixed July 08, 2026, as the record date for determining dividend eligibility. Shareholders are advised that dividend income is now taxable in the hands of shareholders, and the company will be required to deduct tax at source (TDS) at the time of payment.
The announcement details the TDS provisions for both resident and non-resident shareholders, including various forms and documents required to claim exemptions or avail benefits under Double Taxation Avoidance Agreements (DTAA). Specific procedures and deadlines are provided for submission of these documents by July 08, 2026, to ensure appropriate tax deduction. Shareholders are also reminded to update their bank account details for timely dividend credit.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.